In-Person Access Only | 1.75 CE/CME Credits

The Cancer Updates Conference will consist of educational activities designed to meet the needs of medical oncologists, pharmacists, advanced practitioners, and nurses involved in the treatment of GU cancers and hematological malignancies. Each agenda is comprised of presentations that will break down the most clinically relevant information applicable to community care. This dinner program will be hosted as an in-person event only.

Conference Agenda
Tuesday, September 9, 2025

5:15 PM
Networking and Cocktails

5:30 PM
Welcome and Opening Remarks
Tapan Kadia, MD | MD Anderson Cancer Center
Mike Lattanzi, MD, MS | Texas Oncology

5:35 PM
Bladder and RCC
Mike Lattanzi, MD, MS | Texas Oncology

6:05 PM
Updates in Prostate
Andrew Hahn, MD | MD Anderson Cancer Center

6:35 PM
Break and Exhibits

6:50 PM
Non CME Session- Pfizer - Review of Evidence-Based Data for an Antibody -Drug Conjugate in combination with a PD-1 inhibitor for 1L la/mUC
Devesh Pandya, MD | Oncology Consultants, P.A.

7:35 PM
Updates in AML
Tapan Kadia, MD | MD Anderson Cancer Center

8:05 PM
Updates in CLL
Nitin Jain, MD | MD Anderson Cancer Center

8:35 PM
Adjourn

Agenda Subject To Change. All times are CST.

• Learning Objectives

  • Review recent clinical advances in the treatment of GU cancers and hematologic malignancies, with a focus on the most relevant data from recent studies and clinical trials.

  • Evaluate the role of emerging therapies in GU cancers and hematologic malignancies, treatment, including new medications, targeted therapies, and immunotherapies.

  • Apply evidence-based strategies to improve patient outcomes in community oncology settings, focusing on the integration of new treatment approaches.

  • Assess and manage side effects and toxicities associated with current and emerging therapies in GU cancers and hematologic malignancies, patients.

  • Discuss multidisciplinary care approaches that enhance collaboration between oncologists, pharmacists, nurses, and advanced practitioners in treating GU cancers and hematologic malignancies.

• Accreditation Information | 1.75 CE/CME Credits

  In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

  Nurses (ANCC) Credit Designation

  Amedco LLC designates this activity for a maximum of 1.75 ANCC contact hours.

  Physicians (ACCME) Credit Designation

  Amedco LLC designates this live activity for a maximum of 1.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

  Amedco LLC designates this activity for a maximum of 1.75 knowledge-based CPE contact hours.

  NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.

• What to Expect | In-Person Learners

  • Free registration for all healthcare providers

  • Expert sessions that present the most clinically relevant data, research, and clinical strategies

  • Real-time discussion and debate

  • Networking with peers, colleagues, and medical professionals

  • Access to the latest industry information and resources